pI: 7.471 |
Length (AA): 1166 |
MW (Da): 128118 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
NA% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_158005)
Species | Accession | Gene Product |
---|---|---|
Trypanosoma brucei gambiense | Tbg972.10.8490 | T. brucei spp.-specific protein |
Trypanosoma brucei | Tb10.v4.0249 | Cullin family/Cullin protein neddylation domain containing protein, putative |
Trypanosoma brucei | Tb927.10.6930 | Cullin family/Cullin protein neddylation domain containing protein, putative |
Trypanosoma cruzi | TcCLB.510183.30 | Cullin family/Cullin protein neddylation domain containing protein, putative |
Trypanosoma cruzi | TcCLB.503637.20 | Cullin family/Cullin protein neddylation domain containing protein, putative |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.